and others have reported prolonged and/or severe COVID-19 in patients with marked reductions in CD19+ B-cells and CD4+ T-cells, and an increased proportion of exhausted CD4+ T-cells following treatment with bendamustine combined with anti-CD20 antibodies (13, 16). Here, CD19 is linked to COVID-19.